Business Context and Reporting Period
Company: ImmunityBio, Inc. (IBRX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2025
Reporting Period: Event date of July 29, 2025 (Court Order) and August 8, 2025 (Filing date).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on legal proceedings and corporate governance matters.
Material Changes and Events
The primary event reported is the preliminary approval by the United States District Court for the Southern District of California of a proposed settlement regarding stockholder derivative actions. The specific actions include:
- Van Luven v. Soon-Shiong et al. (Case No. 3:24-cv-02014-GPC-VET)
- Barbieri v. Soon-Shiong, et al. (Case No. 3:25-cv-00416-AGS-JLB)
- Shin v. Soon-Shiong, et al. (Case No. 3:25-cv-00423-JAH-DDL)
The settlement, based on a Stipulation entered in May 2025, requires the Company to adopt corporate governance reforms and pay attorneys' fees. In exchange, the derivative actions will be fully released and dismissed.
Guidance, Outlook, and Risks
Settlement Terms and Funding: The Company expects the attorneys' fees associated with the settlement to be funded by its insurance carrier. The filing text does not provide a specific dollar amount for these fees.
Next Steps: A final approval hearing is scheduled for November 4, 2025.
Risks and Contingencies: The settlement is subject to final court approval. Until the final hearing, the outcome remains contingent on the Court's decision.
Investor Verification Checklist
- Verify the final outcome of the settlement at the November 4, 2025, court hearing.
- Review the specific corporate governance reforms detailed in the attached Stipulation and Settlement Agreement (Exhibit 99.2).
- Confirm the actual cost of attorneys' fees and whether the insurance carrier fully covers the expense as expected.
- Monitor for any future disclosures regarding the impact of these governance changes on the Company's operations.